CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Lifestyle Modifications for Preventing and Treating Heart Failure Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5)

Original Research16 Sep 2019

JOURNAL:Circulation. Article Link

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial

Nassif ME, Windsor S, DEFINE-HF Investigators. Keywords: SGLT-2 inhibitors; HFrEF; T2DM; Dapagliflozin effect

FULL TEXT PDF